ArticlePediatric pulmonology2015
Metabolomics analysis identifies novel plasma biomarkers of cystic fibrosis pulmonary exacerbation.
Article in Pediatric pulmonology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 66 citations in OpenAlex.
- Circulating Metabolite Biomarkers of Glycemic Control in Youth-Onset Type 2 Diabetes.Diabetes care · 2024Trial
- The Cytidine N-Acetyltransferase NAT10 Promotes Thalamus Hemorrhage-Induced Central Poststroke Pain by Stabilizing Fn14 Expression in Thalamic Neurons.Molecular neurobiology · 2025Article
- Changes in fecal lipidome after treatment with ivacaftor without changes in microbiome or bile acids.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2024Article
- N4-acetylcytidine modifies primary microRNAs for processing in cancer cells.Cellular and molecular life sciences : CMLS · 2024Article
- Association of Metabolites, Nutrients, and Toxins in Maternal and Cord Serum with Asthma, IgE, SPT, FeNO, and Lung Function in Offspring.Metabolites · 2023Article
- Proteomics and metabolomics profiling reveal panels of circulating diagnostic biomarkers and molecular subtypes in stable COPD.Respiratory research · 2023Article
- NAT10-mediated RNA acetylation enhances HNRNPUL1 mRNA stability to contribute cervical cancer progression.International journal of medical sciences · 2023Article
- Metabolomics of airways disease in cystic fibrosis.Current opinion in pharmacology · 2022Review
- Sweat metabolomics before and after intravenous antibiotics for pulmonary exacerbation in people with cystic fibrosis.Respiratory medicine · 2022Article
- Mechanistic Investigation of Xuebijing for Treatment of Paraquat-Induced Pulmonary Fibrosis by Metabolomics and Network Pharmacology.ACS omega · 2021Article
- Metabolic reprogramming: A driver of cigarette smoke-induced inflammatory lung diseases.Free radical biology & medicine · 2021Review
- Distinctive metabolic profiles between Cystic Fibrosis mutational subclasses and lung function.Metabolomics : Official journal of the Metabolomic Society · 2021Article
- Emerging role of N4-acetylcytidine modification of RNA in gene regulation and cellular functions.Molecular biology reports · 2020Review
- Utilizing centralized biorepository samples for biomarkers of cystic fibrosis lung disease severity.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2020Article
- The Processing, Gene Regulation, Biological Functions, and Clinical Relevance of N4-Acetylcytidine on RNA: A Systematic Review.Molecular therapy. Nucleic acids · 2020Review
- Untargeted Metabolomics Analysis of Esophageal Squamous Cell Carcinoma Discovers Dysregulated Metabolic Pathways and Potential Diagnostic Biomarkers.Journal of Cancer · 2020Article
- A comprehensive analysis of metabolomics and transcriptomics in non-small cell lung cancer.PloS one · 2020Article
- Metabonomics reveals altered metabolites related to inflammation and energy utilization at recovery of cystic fibrosis lung exacerbation.Metabolism open · 2019Article
- Urinary metabolomics reveals unique metabolic signatures in infants with cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2019Article
- Mapping targetable inflammation and outcomes with cystic fibrosis biomarkers.Pediatric pulmonology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundCystic fibrosis (CF) lung disease is characterized by infection, inflammation, lung function decline, and intermittent pulmonary exacerbations. However, the link between pulmonary exacerbation and lung disease progression remains unclear. Global metabolomic profiling can provide novel mechanistic insight into a disease process in addition to putative biomarkers for future study. Our objective was to investigate how the plasma metabolomic profile changes between CF pulmonary exacerbation and a clinically well state.
methodsPlasma samples and lung function data were collected from 25 CF patients during hospitalization for a pulmonary exacerbation and during quarterly outpatient clinic visits. In collaboration with Metabolon, Inc., the metabolomic profiles of matched pair plasma samples, one during exacerbation and one at a clinic visit, were analyzed using gas and liquid chromatography coupled with mass spectrometry. Compounds were identified by comparison to a library of standards. Mixed effects models that controlled for nutritional status and lung function were used to test for differences and principal components analysis was performed.
resultsOur population had a median age of 27 years (14-39) and had a median FEV1 % predicted of 65% (23-105%). 398 total metabolites were identified and after adjustment for confounders, five metabolites signifying perturbations in nucleotide (hypoxanthine), nucleoside (N4-acetylcytidine), amino acid (N-acetylmethionine), carbohydrate (mannose), and steroid (cortisol) metabolism were identified. Principal components analysis provided good separation between the two clinical phenotypes.
conclusionsOur findings provide putative metabolite biomarkers for future study and allow for hypothesis generation about the pathophysiology of CF pulmonary exacerbation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.